![conference banner](/images/conference-banner.jpeg)
Abstract
Cancer is one of the leading causes of death in the United States along with heart disease. The hallmark of cancer treatment has been conventional chemotherapy. Chemotherapeutic drugs are designed to target not only rapidly dividing cells, such as cancer cells, but also certain normal cells, such as intestinal epithelium. Over the past several years, a new generation of cancer treatment has come to the forefront, i.e, targeted cancer therapies. Like conventional chemotherapy, targeted cancer therapies use pharmacological agents that inhibit growth, increase cell death and restrict the spread of cancer. As the name suggests, targeted therapies interfere with specific proteins involved in tumorigenesis. Rather than using broad base cancer treatments, focusing on specific molecular changes which are unique to a particular cancer, targeted cancer therapies may be more therapeutically beneficial for many cancer types, including lung, colorectal, breast, lymphoma and leukemia. Moreover, recent advances have made it possible to analyze and tailor treatments to an individual patient’s tumor. There are three main types of targeted cancer therapies; 1) monoclonal antibodies, 2) small molecule inhibitors and 3) immunotoxins. This review will discuss these three classes of targeted therapies in detail, as well as the biology behind targeted cancer therapies.
Keywords: Cancer therapies, chemotherapy, immunotoxins, monoclonal antibodies, small molecule inhibitors.
Current Drug Discovery Technologies
Title:Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Volume: 12 Issue: 1
Author(s): Troy A. Baudino
Affiliation:
Keywords: Cancer therapies, chemotherapy, immunotoxins, monoclonal antibodies, small molecule inhibitors.
Abstract: Cancer is one of the leading causes of death in the United States along with heart disease. The hallmark of cancer treatment has been conventional chemotherapy. Chemotherapeutic drugs are designed to target not only rapidly dividing cells, such as cancer cells, but also certain normal cells, such as intestinal epithelium. Over the past several years, a new generation of cancer treatment has come to the forefront, i.e, targeted cancer therapies. Like conventional chemotherapy, targeted cancer therapies use pharmacological agents that inhibit growth, increase cell death and restrict the spread of cancer. As the name suggests, targeted therapies interfere with specific proteins involved in tumorigenesis. Rather than using broad base cancer treatments, focusing on specific molecular changes which are unique to a particular cancer, targeted cancer therapies may be more therapeutically beneficial for many cancer types, including lung, colorectal, breast, lymphoma and leukemia. Moreover, recent advances have made it possible to analyze and tailor treatments to an individual patient’s tumor. There are three main types of targeted cancer therapies; 1) monoclonal antibodies, 2) small molecule inhibitors and 3) immunotoxins. This review will discuss these three classes of targeted therapies in detail, as well as the biology behind targeted cancer therapies.
Export Options
About this article
Cite this article as:
Baudino A. Troy, Targeted Cancer Therapy: The Next Generation of Cancer Treatment, Current Drug Discovery Technologies 2015; 12 (1) . https://dx.doi.org/10.2174/1570163812666150602144310
DOI https://dx.doi.org/10.2174/1570163812666150602144310 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
Call for Papers in Thematic Issues
Advancements in Computational Methods for Drug Design
This thematic issue delves into the cutting-edge computational methodologies revolutionizing drug design. Emphasizing the integration of in silico techniques, this collection highlights advancements in some computational methods, as: molecular docking, molecular dynamics, QSAR (Quantitative Structure-Activity Relationship) and free energy calculations. These approaches enhance the efficiency of drug discovery, reduce costs, ...read more
Disease Modelling: Emerging Frontiers in Disease Modelling: Data to Drug Discovery in Bioinformatics in Precision Medicine and Health Science
The special issue on "Emerging Frontiers in Disease Modelling: Data to Drug Discovery in Bioinformatics in Precision Medicine and Health Science" aims to explore the transformative role of bioinformatics in bridging the gap between extensive biological data and the development of targeted therapies. This issue will highlight cutting-edge research and ...read more
Novel drug delivery therapeutics: Opportunities and challenges for combating diseases
The field of drug delivery therapeutics has undergone significant transformation with the emergence of innovative technologies designed to enhance therapeutic efficacy and patient outcomes. As traditional drug administration methods encounter limitations in terms of efficacy, safety, and patient compliance, novel drug delivery systems offer promising solutions to these challenges. Advancements ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Caffeic Acid Phenethyl Ester (CAPE) in Diabetes
Current Medicinal Chemistry The Oxido-reductase Activity of the Apoptosis Inducing Factor: A Promising Pharmacological Tool?
Current Pharmaceutical Design New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells
Current Stem Cell Research & Therapy The Failing Heart in Pediatric Dilated Cardiomyopathy Caused by Excessive Water Drinking: A Case Report and Brief Review
New Emirates Medical Journal Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence
Current Diabetes Reviews Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Necrosis Avidity of Organic Compounds: A Natural Phenomenon with Exploitable Theragnostic Potentials
Current Medicinal Chemistry Enteral and Parenteral Nutrition Therapy for Crohns Disease
Current Pharmaceutical Design Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease
Reviews on Recent Clinical Trials Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design IRAKs: Key Regulatory Kinases of Innate Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Late Sodium Current Inhibition: The Most Promising Antiarrhythmic Principle in the Near Future?
Current Medicinal Chemistry Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence?
Current Medicinal Chemistry Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design